Curative goals: is intensive chemotherapy the antileukaemic standard of care?
Redefining survival expectations in high-risk* AML
Pursuing long-term survival in the real world
Learning Objectives & Overview
High-risk* acute myeloid leukaemia (AML) has a poor prognosis and remains a therapeutic challenge.1 In this sponsored Symposium, recorded at the 3rd European School of Haematology meeting on how to diagnose and treat acute leukaemias (ESH-AL), three leading experts present and discuss clinical and real-world evidence on the use of Vyxeos Liposomal (Daunorubicin 44mg / Cytarabine 100mg) for the treatment of high-risk* AML, and how this might change the management of the condition.2–5
*High risk AML is defined as newly diagnosed, therapy related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
After watching this activity, participants should be better able to:
- Discuss the diagnosis, classification and prognosis of high-risk* AML
- Review the clinical and real-world evidence on the use of Vyxeos Liposomal for the treatment of high-risk* AML
- Discuss the impact this evidence may have on the management of high-risk*AML
Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email to email@example.com
- Granfeldt Østgård LS, et al. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol. 2015;33:3641–9.
- Lancet JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481–e491.
- Chiche E, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. Blood Adv. 2021;5:176–184.
- Guolo F, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020;10:96.
- Rautenberg C, et al. Real-world Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer J. 2021;11:164.